SMC accepts first licensed treatment for newly diagnosed AL amyloidosis

The SMC has accepted the first licensed treatment for adults with newly diagnosed systemic light chain (AL) amyloidosis.

Darzalex® (daratumumab) in combination with bortezomib, cyclophosphamide and dexamethasone (DBCd), has demonstrated a deep and durable response, that reduces organ deterioration, and improves quality of life, compared to bortezomib, cyclophosphamide, and dexamethasone (BCd) alone.

read more